Drawing for PAIONEER

USPTO serial 78506558

PAIONEER

Reviewed by CopyMark Law Group

Reg. 3734289Status 710
Filing date
Status date
Registration date
Jan 5, 2010
Examiner
REGAN, JOHN B
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with PAIONEER?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Gary D. Krugman

Gary D. Krugman SUGHRUE MION, PLLC2100 PENNSYLVANIA AVENUE, NWWASHINGTON, DC 20037-3213UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Reagents for scientific or medical research use; diagnostic reagents for scientific or research use, biochemical reagents for scientific or medical research use; reagents for scientific or research use, none of the foregoing goods for use in the agricultural industry, including biopharmingSECTION 8 - CANCELLED—
005Pharmaceutical preparations, namely, pharmaceutical preparations derived from living organism proteins and peptides for treatment and diagnosis of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; pharmaceutical anti-inflammatory preparations; pharmaceutical nutriceutical preparations for the treatment of strokes, neuron damage, thrombotic diseases, tumors, cancer, heart disease including heart failure, circulation disorders, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; blood clotting test kits comprised of medical diagnostic reagents; medical and clinical diagnostic reagents for clinical or medical laboratory use, none of the foregoing goods for use in the agricultural industry, including biopharmingSECTION 8 - CANCELLED—
035Computerized database management, namely, editing, evaluating and processing data for third partiesSECTION 8 - CANCELLED—
041Educational services, namely, providing informational events in the nature of seminars and workshops in the fields of pharmacology, medical procedures, product research and development of medical devices and pharmaceutical preparations, none of the foregoing services offered to the agricultural industry, including biopharmingSECTION 8 - CANCELLED—
042Database development for others; computer programming for others; performing chemical analyses for others; technical consultation in the field of biotechnology; licensing of intellectual property; services of a biotechnological laboratory, namely, conducting lab research for others in the field of drug research and development; pharmaceutical consulting, namely, providing pharmaceutical advice to others regarding governmental regulatory laws and practices, performing pre-clinical studies, quality control; preparation of expert opinions in the field biology, molecular biology, pharmacology, chemistry, bio-technology, bio-chemistry, product research and development of medical devices and pharmaceutical preparations, and molecular diagnostic services of a bio-chemist, namely, product research and development services for others in the area of gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development and identifying, designing and analyzing therapeutic proteins; diagnostic services in the field of molecular science, comparative genome analysis, DNA-arrays including DNA-microarrays, creation of nucleic acid libraries, screening of nucleic acid libraries; performance of pre-clinical studies, namely, conducting and managing pre-clinical trials and studies of pharmaceutical, bio-technology and health care products; bio-chemical and biotechnological research and development for others, namely, bio-technological research and development regarding medical disease diagnosis and pharmacology, namely, prenatal diagnostic and identification of hereditary factors leading to diseases, identification of genes involved in the formation of cancer, identification of target molecules for cancer treatment. scientific research on and development of medical diagnostic equipment and pharmaceutical preparations and products for the treatment of tumors, cancer, dermatological diseases, spinal cord injuries, osteoporosis, cell degeneration, allergies, endocrine diseases, hormonal imbalances, nervous diseases, diseases of the respiration system, kidney and bladder diseases, infectious diseases, gastrointestinal diseases, pain and epilepsy; scientific and technical consulting for others in the field of medical science and drug research, namely, identifying, designing, and developing drugs, specifically, therapeutic proteins, gene expression analysis, namely, proteogenomic profiling, DNA-sequencing, drug target development, identification and design; medical science research services for others, namely, prenatal diagnostics, molecular diagnostics, comparative genome analysis, DNA-arrays including DNA microarrays, creating and screening of nucleic acid libraries, identifying hereditary factors leading to diseases, identifying genes involved in the formation of cancer, identification of target molecules for cancer treatment, none of the foregoing services offered to the agricultural industry, including biopharmingSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Aug 12, 2016C8..CANCELLED SEC. 8 (6-YR)—
Jan 5, 2010R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jan 4, 2010DOCKASSIGNED TO EXAMINER—
Dec 1, 2009TMBNTTAB RELEASE CASE TO TRADEMARKS—
Dec 1, 2009OP.TOPPOSITION TERMINATED NO. 999999—
Dec 1, 2009OP.DOPPOSITION DISMISSED NO. 999999—
Jan 15, 2009OP.IOPPOSITION INSTITUTED NO. 999999—
Nov 7, 2008CRTPREG. CANCELLED - RESTORED TO PENDENCY—
Oct 31, 2008APETASSIGNED TO PETITION STAFF—
Oct 10, 2008RCIIREQUEST TO CANCEL INADVERTENTLY ISSUED REGISTRATION RECEIVED—
Sep 30, 2008R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Aug 14, 2008ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Aug 14, 2008ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Jul 15, 2008PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 25, 2008NPUBNOTICE OF PUBLICATION—
Jun 6, 2008PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 3, 2008CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 3, 2008ACECAMENDMENT FROM APPLICANT ENTERED—
Jun 3, 2008XAECEXAMINER'S AMENDMENT ENTERED—
Jun 2, 2008ALIEASSIGNED TO LIE—
Jun 2, 2008GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Jun 2, 2008GNEAEXAMINERS AMENDMENT E-MAILED—
Jun 2, 2008CNEAEXAMINERS AMENDMENT -WRITTEN—
Jun 2, 2008ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Jun 2, 2008ADBS1(B) BASIS DELETED; NEW BASIS REQUESTED—
Jun 2, 2008IUCNNOTICE OF ALLOWANCE CANCELLED—
Apr 18, 2008EX4GSOU EXTENSION 4 GRANTED—
Apr 18, 2008EXT4SOU EXTENSION 4 FILED—
Apr 18, 2008EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 16, 2008ATRQATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED—
Apr 16, 2008PCBGPETITION TO DIRECTOR - CHANGE BASIS - GRANTED—
Apr 16, 2008APETASSIGNED TO PETITION STAFF—
Apr 11, 2008CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Apr 11, 2008PDCBPETITION TO DIRECTOR - CHANGE BASIS - RECEIVED—
Apr 11, 2008MAILPAPER RECEIVED—
Oct 22, 2007EX3GSOU EXTENSION 3 GRANTED—
Oct 22, 2007EXT3SOU EXTENSION 3 FILED—
Oct 22, 2007EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jul 27, 2007EX2GSOU EXTENSION 2 GRANTED—
Apr 18, 2007EXT2SOU EXTENSION 2 FILED—
Apr 18, 2007EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Oct 11, 2006EX1GSOU EXTENSION 1 GRANTED—
Oct 11, 2006EXT1SOU EXTENSION 1 FILED—
Oct 11, 2006EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Apr 25, 2006NOAMNOA MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 4, 2006ETOPEXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED—
Oct 25, 2005ACECAMENDMENT FROM APPLICANT ENTERED—
Oct 25, 2005MAILPAPER RECEIVED—
Oct 20, 2005ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Oct 4, 2005PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 14, 2005NPUBNOTICE OF PUBLICATION—
Aug 12, 2005PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 10, 2005ALIEASSIGNED TO LIE—
Aug 2, 2005CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 2, 2005ACECAMENDMENT FROM APPLICANT ENTERED—
Jul 27, 2005CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 27, 2005MAILPAPER RECEIVED—
Jun 2, 2005GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 2, 2005CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 2, 2005DOCKASSIGNED TO EXAMINER—
Nov 5, 2004NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance